emerg tripl threat autoimmun initi buy pt
ipo octob certain histor financi data unavail
potenti best-of-bre autoimmune-focus compani
initi coverag inc newly-emerg biotechnolog
compani origin spun medimmunea subsidiari
astrazenecain earli viela helm longtim
medimmun execut dr bing yao establish order
advanc sever clinical-stag medimmun asset first
inebilizumab human monoclon antibodi target
antigen known express surfac immun cell
particularli cell inebilizumab broad applic across multipl
autoimmun inflammatori disord known mediat
cell demonstr believ best-in-class
clinic data neuromyel optica spectrum disord nmosd
indic inebilizumab alreadi file approv
 biolog licens applic bla inebilizumab
accept review fda approv decis
 prescript drug user fee act pdufa date june
expect inebilizumab garner command share
market nmosd given best-in-class profil clinic
impact standpoint also respect safeti conveni
administr everi six month viela also develop
fusion protein design bind ligand
activ cell block interact cell
potenti bind partner anticip could
impact kidney transplant reject sjgren syndrom
candid could commerci use sale market
infrastructur intend deploy support inebilizumab
rate buy price target
differenti profil inebilizumab nmosd inebilizumab
afucosyl human kappa monoclon
antibodi mab absenc fucos inebilizumab result
enhanc affin fcgr iiia thu increas
may permit broader faster direct cell deplet
vs blockad histor princip
therapeut intervent strategi cell-medi diseas
risk reduct vs placebo risk reduct vs
placebo patient unlik
satralizumab eculizumab princip competitor nmosd
inebilizumab agent show impact disabl
endpoint pivot test final note inebilizumab safeti
profil appear superior sever advers
event sae rate vs placebowith similar ae rate vs
placebo vs eculizumab black box warn
requir rabi vaccin administr would also point
eculizumab requir inpati infusion-bas administr
everi week satralizumab administ once-monthli via
subcutan inject inebilizumab contrast need given
everi six month via infus initi induct
definit distribut analyst rate analyst certif disclosur pleas refer page report
consider near-term commerci opportun expect inebilizumab launch gener peak sale
roughli annual alon within nmosd indic investor note sale
forc roughli rep alreadi fulli hire thu compani abl effect time rapid launch
investor awar sale forc extens experi exclus hire compani
substanti expertis autoimmun inflammatori diseas arena everi viela rep previous either
produc sale person prior sale team work
possibl tripl threat autoimmun diseas indic ascrib partial valu pipelin
still retain consid conserv project exampl estim peak market penetr
inebilizumab nmosd despit believ compel valu proposit drug
indic price assumpt util start annual cost per patient inebilizumab eculizumab
highest-pr agent current approv treat nmosdi current price roughli annual believ
inebilizumab could gener roughli annual peak sale treatment myasthenia gravi wherein project
peak market penetr rate roughli translat patient therapi anticip
inebilizumab total peak sale across nmosd myasthenia gravi kidney transplant desensit indic could
reach roughli view could reach total peak sale roughli sjgren
syndrom kidney transplant reject even project contribut third clinical-stag
candid mab potenti applic cutan system lupu erythematosu
anticip could establish tripl threat autoimmun three productsinebilizumab
commerci use specialti sale forc current assumpt also conserv
assum contribut sale ignor potenti molecul ex-u market
compani could potenti optim valu via strateg partnership
solid pedigre strong balanc sheet feel pedigre pipelin constitut signific advantag
sinc molecul origin design develop medimmun track record medimmun
independ entityprior astrazeneca acquisitioni impress medimmun origin brought multipl biolog drug
market notabl synagi palivizumab prevent respiratori syncyti viru rsv infect
synagi annual franchis peak wake spin-out medimmun attract seri
fund earli follow seri financ round led
temasek terra magnum capit partner compani trajectori culmin solidli support initi public
offer ipo octob provid total gross proce sale roughli share
common stock per share includ exercis full over-allot total roughli share highli
respect institut investor date also includ dimens capit boyu capit cormor asset manag hbm
healthcar invest hillhous capit vike global investor believ compani end nearli
cash balanc sheet expect suffici fund oper late past introduct
inebilizumab market
catalyst-rich year ahead provid multipl valu inflect point feel investor particularli enthus
viela prospect given potenti catalyst initi phase trial inebilizumab kidney
transplant sensit possibl approv inebilizumab nmosd june launch inebilizumab
 treatment nmosd possibl complet phase trial sjgren syndrom
submiss investig new drug ind applic subsequ initi mid-stag test
inebilizumab myasthenia gravi could potenti becom highest-valu indic agent
submiss ind initi phase trial inebilizumab diseas indic current
includ project interim data phase trial cutan lupu erythematosu cle
advanc mid-stag test candid
valuat risk current valu use discount cash flow dcf -base approach ascrib
total compani two advanc clinical-stag pipelin asset inebilizumab assign
probabl approv inebilizumab nmosd sinc drug alreadi success complet phase clinic
develop bla file accept review fda furthermor assign probabl
respect inebilizumab myasthenia gravi kidney transplant desensit given substanti clinic evid
indic target antigen therapeut impact indic consid proof-of-
concept data gener inebilizumab arena date util probabl approv
two indicationskidney transplant reject sjgren syndrometak account consider
evid support therapeut relev pathway indic fact enter
clinic test employ discount rate believ reason consid fact viela
development-stag entiti also take account focus natur nich market compani target
substant industri expertis manag team well proven natur sale forc final util
termin growth rate consid conserv light fact current ascrib valu
potenti candid market outsid includ potenti contribut futur sale
compani third candid valuat assess yield price object per share assum
share common stock outstand
market segment market model
review outlook
histor incom statement financi project
histor balanc sheet financi project
histor statement flow financi project
tabl content
found
headquart gaithersburg md
spin-out medimmun global
biolog arm astrazeneca
launch earli seri
financ consortium led boyu capit
dimens capit hillhous capit
secur seri fund
ipo octob gross proce
human monoclon antibodi mab design
autoantibodi implic autoimmun diseas
treatment neuromyel
optica rare autoimmun diseas attack
optic nerv spinal cord approxim
patient
receiv orphan drug breakthrough therapi
 fda orphan
design european medicin agenc
treatment nmosd
desensit myasthenia gravi mg
autoimmun sever inflammatori diseas
select target critic pathway
robust pipelin five clinic preclin
autoantibodi co-stimulatori
focus area high unmet medic need
order creat larg market opportun
patient neuromyel optica
trial data broad patient
bla accept review fda
pdufa date june
fusion protein design bind ligand
activ cell block
interact cell
inhibit stimul dendrit cell monocyt
cell reduc product pro-
combin effect
immunomodul lead
dampen inflammatori respons
syndrom kidney transplant reject
treatment sjgren
human mab design bind cell
surfac molecul specif plasmacytoid dendrit
cell pdc lead pdc deplet
interferon
overproduct
cytokin secret pdc
develop treatment cutan lupu
includ overal valuat compani
bla accept review aug
pdufa date june
 wainwright co estim adapt inc
 wainwright co estim adapt inc
attack individu
healthi cell tissu
immun system
hone critic
biolog pathway share
current focu three
clinical-
spin-out astrazeneca
medimmun earlier
respons bring
prevent respiratori
infect infant
caiv-t needle-fre
astrazeneca agre
acquir medimmun
billion
biotech deal
bolster portfolio
part reorgan unit astrazeneca retir medimmun brand
earli effort simplifi compani structur
maryland oper remain one astrazeneca three global site
spun focu develop medimmun
dedic develop commerci novel life-chang
medicin patient wide rang autoimmun sever inflammatori
led ceo bing yao roster five key biolog drug program aim
autoimmun diseasethre clinic trial remaind slate
initi first half
head
year experi biopharmaceut industri proven
track record success discoveri develop program
recent tenur medimmun astrazeneca senior vice presid
head respiratori
inflamm autoimmun ime
integr leadership involv develop approv three
respiratori immune-oncolog
autoimmun
dr yao also svp head immuno-oncolog franchis astrazeneca
previou leadership posit genentech aventi
dr yao receiv ph
microbiolog immunolog
univers iowa follow postdoctor work immunex
mr chan join vice-president head financ corpor strategi
support multipl capit rais involv lead
previous director investor relat astrazeneca prior
held sever role increas respons genentech-roch
mr chan recipi execut certif stanford univers
univers california berkeley haa wharton school
univers pennsylvania earn degre
univers toronto
dr drappa two decad experi research
develop inflamm autoimmun therapeut field
recent
tenur vice presid clinic medimmun
function
head clinic
autoimmun cardiovascular metabol infecti diseas
receiv medic degre univers cologn germani
ph immunolog weill cornel school medicin
vice-president head market access
ms menach year experi biotech industri
special orphan ultra-orphan drug launch
previous head market access
senior director market access account np pharma
acquir shire part takeda
success launch two first-in-class ultra-orphan product three year
vice-president head busi develop oper
dr ren year experi biopharmaceut busi
special function manag qualiti busi
develop procur contract function
previous medimmun china lead
initi china
autoantibodi pathway target inebilizumab antibodi treatment
adapt inc
differenti antibody-
secret plasmablast
plasma cell perpetu
immun respons attack
bodi tissu
inebilizumab human
design bind
cell surfac
molecul cell
initi deplet
plasmablast
decreas product
pathogen autoantibodi
henc autoimmun
pathway target inebilizumab central multipl autoimmun indic larg unmet need
aris misdirect
direct
bodi healthi cell
tissu
inflamm ensu
mediat
larg unmet
medic need
treatment sever
current treatment
steroid non-target
result increas
infect incid
relaps autoimmun inflammatori diseas
autoantibodi secret subset cell plasmablast plasma cell attack nativ tissu oppos
foreign pathogen
kidney transplant desensit patient await
process remov harm antibodi bloodstream improv patient outcom
 cell-medi autoantibodi pathway central produc autoantibodi detriment
myasthenia gravi mg
autoimmun disord postsynapt neuromuscular junction
fluctuat weak ocular bulbar
limb respiratori muscl mg caus
autoantibodi attack acetylcholin receptor achr muscl endplat autoantibodi
attack muscl specif kinas musk
diseas estim
associ autoantibodi pathway central nmosd
autoimmun condit affect multipl organ tissu includ pancrea eye socket salivari
gland peritoneum present tumor-lik swell infiltr plasma cell
origin cell-medi autoantibodi pathway
foundat america sourc
target cellular compon core pathway rather downstream cellular
product give inebilizumab competit edg treatment nmosd
home
design
deplet
cell
compon
inflammatori respons
repres advantag
compet therapi
addit inebilizumab
engin remov fucos
sugar group result
enhanc affin lead
increas antibody-depend cellular
cytotox adcc render
effect deplet cell
plasmablast plasma cell
inebilizumab
target plasmablast
plasma cell
addit cell
drug block
mechan action
signalingit
product
limit
strategi
involv mani
direct target
bound
flaw
complement integr
innat
inebilizumab posit translat clinic best-in-class safeti efficaci conveni price
patient pool
vari level
monotherapi
oppos
lowest incid
side effect
sakurastar monotherapi add-on
includ patient broad
sever patient
 broad patient sever
day everi
weekli week
week everi week
week everi week
sae pt two
rate vs
rate irr vs
estim base
public compani mention tabl compris alexion pharmaceut rate roch rog vx rate
adapt inc
placebo-adjust cross-trial safeti comparison underscor superior safeti profil inebilizumab
placebo
comparison lower
particularli compar
inebilizumab show promis treat broad scope indic
 patient
mg rare autoimmun diseas
patient present weak
ocular bulbar limb respiratori
drachman et al harrison principl intern medicin mcgraw-hil
neurotransmitt neuromuscular
mg caus autoantibodi origin cell-
mediat pathway attack acetylcholin receptor
achr muscl endplat attack muscl
 patient
diseas
fibro-inflammatori condit
present lesion one
organ throughout bodi
pathophysiolog
involv b-cell-medi
autoantibodi pathwaydespit
approach could prove
patient await transplant
patient kidney
transplant wait-list
lower chanc
organ
result
high level
aris
exposur
sensit
employ
pivot
intervent
effort improv
competit landscap inebilizumab myasthenia gravi
multipl generically-avail medic exist treat myasthenia gravi mg yet none consid particularli effect consider side
effect risk corticosteroid immunosuppress drug carri risk broad-spectrum immun system compromis incid opportunist
infect acetylcholinesteras inhibitor associ nausea vomit diarrhea muscl cramp weight loss insomnia issu
brand-nam agent approv treat mg gammagard exist sever intraven immun globulin ivig prepar
rituxan gradual start face competit biosimilar agent soliri ultra-high price drug due origin approv
treat paroxysm nocturn hemoglobinuria pnh mention earlier report given high price soliri consid viabl competitor
inebilizumab also develop ultomiri biobett soliri treatment mg ultomiri phase develop howev believ
alexion like price ultomiri level similar soliri impli neither ultomiri soliri would like manag outcompet inebilizumab
lastli note presenc anti-fcrn monoclon antibodi constitut signific potenti long-term threat inebilizumab market penetr
mg howev appear far enough ahead inebilizumab command lead furthermor note peak sale assumpt
involv roughli patient mg therapi inebilizumab see market model section thu feel project adequ account competit
drug namegener namecompani nametickerratingmechan actionstagegenericmestinonpyridostigminebausch health companiesbhcbuyacetylcholinesteras inhibitormarketedyesbloxiverzneostigmineeclat snanaacetylcholinesteras inhibitormarketedyesdeltasoneprednisonepfizerpfenot ratedcorticosteroidmarketedyessolu-medrolmethylprednisolonepfizerpfenot ratedcorticosteroidmarketedyesimuranazathioprinemylan nvmylnot ratedpurin metabol inhibitormarketedyessandimmunecyclosporin anovartisnvsnot ratedt lymphocyt inhibitormarketedyescellceptmycophenol mofetilrocherog vxnot ratedpurin metabol inhibitormarketedyestrexallmethotrexateteva industriestevanot ratedantifol antimetabolitemarketedyesgammagardimmun globulin ivbaxt internationalbaxnot ratedimmunoglobulinmarketedyesrituxanrituximabrocherog vxnot monoclon antibodymarketedyessoliriseculizumabalexion salxnnot ratedcompl monoclon antibodymarketednoultomirisravulizumab-cwvzalexion salxnnot ratedlong-act monoclon antibodyphas phosphatecatalyst scprxbuyaminopyridin potassium channel blocker phase srarxnot ratedmacrocycl peptide-bas inhibitorphas seargxnot ratedanti-igg monoclon antibodyphas monoclon antibodyphas smntabuyanti-fcrn monoclon antibodyphas scienc ltd imvtnot ratedanti-fcrn monoclon antibodyphas ucb brnot ratedanti-igg monoclon antibodyphas co ltd tkphfnot monoclon antibodyphas agnanatherapeut vaccin activ immunotherapyphas inc
diseas upsid potenti de-risk element bolster market potenti inebilizumab
includ market model
expect
base phase data obexelimab
ri
decreas
encourag b-cell deplet result n-momentum studi
signific
circul
placebo
includ market model
taken togeth upsid
potenti de-risk element may
provid fuel upsid
repres
either salesperson
previou organ
launch profil
favor motiv sale
market team readi
alreadi hire
full ahead
inebilizumab
sale forc provid solid
foundat launch futur
compani salespeopl
market promot product
monoclon antibodi biolog
indic focus mainli
co-stimulatori pathway target fusion protein base treatment
fusion protein
design bind
bind event block
interact cell
 cell
inhibit
interact cell
differenti plasmablast
plasma cell
provid novel
power way target
adapt inc
mechan action therapeut indic focu
pivot role
well
full antibodi
result safeti
prevent
event caus
cross-link
treatment
platelet
lead platelet
target
complic
doesnt contain
fc antibodi
next-gener therapeut
non-antibodi scaffold design
autoimmun diseas involv inflamm exocrin gland
patient present combin keratoconjunct sicca dri eye xerostomia dri mouth
case rheumatoid arthriti ra interact play critic role
pathogenesi sjgren syndrom
kidney transplant reject lead caus allograft loss
autoimmun respons transplant organ central
reject
costimulatori signal play crucial role perpetu underli inflammatori respons blockad
interact repres promis intervent ensur transplant accept
competitor mechan action
fail phase ss
readout phase
ss expect
develop phase
trial ss
ss
competitor mechan action
phase ra phase
mg sle transplant
reject renal liver
ln
phase fsg
kidney phase
phase fail itp
phase ra phase
ln
competitor mechan action
antova
phase fail ra
phase cd
abandon phase
due safeti ln
abandon due
safeti cd ms sle
preclin ra phase
phase gvhd
sle
itp
iscalimab phase trial result provid benchmark data plan trial sjgren syndrom
primari outcom measur chang eular sjgren
syndrom diseas activ essdai score
baselin week compar placebo
dose intraven subcutan mg/kg
result report lancet rheumatolog
significantli greater improv eular sjgren
syndrom diseas activ essdai score
baselin week compar placebo
averag essdai score decreas point
baselin approxim point week
treatment group
approxim point placebo group
plan proof-of-concept studi evalu
efficaci safeti subject
primari outcom measur chang baselin
sjgren syndrom diseas activ essdai
day popul
chang baselin eular sjgren syndrom
patient report esspri day
dose intraven dosag specifi
similar data seen
iscalimab posit
favor view
confid util treatment kidney transplant reject sjgren syndrom beyond
best-in-class efficaci favor safeti
phase singl ascend dose sad trial healthi
men exhibit dose depend target engag effect
indic proof mechan
follow-up phase trial show dose-depend
decreas autoantibodi level inhibit t-cell depend
antibodi respons bolster case proof principl
addit studi promis dose effect observ
higher dosesmeasur low diseas activ
remiss well autoantibodi level return favor result
encourag absenc thrombot event
util
abstract present american transplant
iscalimab assess
preserv
pathologist score biopsi base chronic allograft
damag index less denot normal
iscalimab associ lower
qualiti
furthermor believ
may also possibl
applic across rang
autoimmun diseas
potenti model
valuat assess
given asset
diseas pathway sale
may overlap
inebilizumab
mark pro-inflammatori cell antibodi treatment induc death
cytokin type
interferon tnf-
design target
bind cell
surfac protein specif
pdc
process cell death
apoptosi pdc
result deplet
pdc may attenu
product proinflammatori
mediat involv
adapt inc
posit tackl autoimmun indic sle-rel diseas cluster
relaps autoimmun inflammatori diseas
autoantibodi secret subset cell plasmablast plasma cell attack
nativ tissu oppos foreign pathogen
data expect
read
first half
cutan
potenti
appli
condit
sle
adapt inc
prudent de-risk withhold model posit potenti valuabl addit
includ
contribut
valuat compani
de-risk part
base posit phase
data
releas decemb
phase lilac
studi primari
endpoint met
activ reduct cutan
system lupu
view need two
three success product becom
powerhous biotech sector evidenc
soliri ultomiri
alexion
vimizim kuvan
biomarin
darzalex tepezza
genmab a/
vedotin tucatinib
seattl genet
could pois becom tripl threat across autoimmun diseas univers beyond
adapt inc
epidemiolog analysi nmosd indic
provid illustr purposesfor addit detail refer
market model later section
market segment sjgren syndrom patient
provid illustr purposesfor addit detail refer market
model later section
compani report center diseas control prevent evaluatepharma wainwright co estim
mab nmosd penetr patient treat annual cost sale nmosd transplant desensit penetr patient treat annual cost sale kidney transplant desensit gravi penetr patient treat annual cost sale myasthenia gravi inebilizumab sale fusion protein sjgren syndrom penetr patient treat annual cost sale sjgren syndrom transplant reject penetr patient treat annual cost sale kidney transplant reject sale inc
project salesinebilizumab
compani report wainwright co estim
inc mm except amount per transplant desensit transplant valu firm debt valu firm per shareproduct launch yearpat expirypeak salesroyaltyprob launch inc
calendar year capit work capit depreci net debt-fre factor net debt-fre ratedcf assumptionsdiscount growth growth factor termin valueperiod inc
review outlook
inebilizumab nmosd manag provid guidanc
total revenu base sale
estim inebilizumab gross margin could approach
estim compani total oper expens trend
higher addit invest clinic trial sale
market activ would potenti includ mileston
payment medimmun upon regulatori approv inebilizumab
treatment nmosd
carryforward feder
end compani feder state net oper
carryforward project futur revenu
tax effect rate exist nol deplet
novemb
common stock outstand approxim option
compani share
forecast dilut net loss per share
estim could roughli end
provid oper runway late
compani oper would cash flow
neg near term compani could turn oper cash
flow posit accord project
unprofit sinc incept may requir
addit capit futur order drive develop
pipelin financ acquisit product pipelin
compani stock could experi above-
averag risk volatil
process obtain regulatori approv fda
regulatori agenc typic arduou complex
regul demand may chang time time
guarante compani product candid would
grant approv time manner
compani product approv may achiev commerci
success due market size penetr rate competit viela
seek self-commerci inebilizumab in-hous
sale forc market infrastructur may involv greater
risk partner establish entiti alreadi
experi autoimmun inflammatori diseas arena
inebilizumab approv treatment nmosd like
compet two product complet success pivot
studi nmosd eculizumab inc
alexion market soliri satralizumab chugai
co ltd chugai affili roch soliri
approv sinc march treatment
paroxysm nocturn hemoglobinuria pnh subsequ
approv octob treatment patient gener
myasthenia gravi june treatment adult
nmosd alexion possess substanti commerci expertis
may prove formid competitor roch one
world
largest pharmaceut compani long-standing track
record commerci experi domain autoimmun
inflammatori diseas accordingli eculizumab satralizumab
could constitut challeng competitor inebilizumab nmosd
eculizumab like compet inebilizumab myasthenia
gravi well agent may applic similar
area beyond nmosd rituxan rituximab market
year therapi b-cell-driven
cancer variou autoimmun disord approv treat
nmosd may appli off-label treatment condit
rituximab origin develop launch roch
gradual start face competit biosimilar version
competit nulojix belatacept origin bristol-my
squibb origin approv
june
compani develop monoclon antibodi candid could
compet includ ucb boehring
novarti among other mani compani
substanti larger far greater resourc
reimburs landscap unit state gradual becom challeng past sever year govern agenc
center medicar medicaid servic becom aggress pursu negoti drug price polit
landscap unit state may subject consider chang disrupt come year driven primarili bipartisan support
broad-bas control implement upon prescript drug price reimburs agenc pharmaci benefit manag pbm
continu demand rebat prescript drug manufactur addit certain reimburs agenc includ limit privat
insur may requir prior author ahead permit usag product patient demonstr non-
respons compet product prior allow move one agent
reli patent trade secret protect product competit competit rife extrem case may lead
lawsuit protect intellectu properti pharmaceut industri highli litigi may success defend
intellectu properti claim challeng compani seek launch competitor drug
secur issu emerg healthcar compani inher volatil increasingli subject develop regulatori risk meet
miss develop commerci mileston may result chang percept firm stock price anticip
volatil subsid near term discuss applic risk factor pleas consult compani sec file
histor incom statement financi project
thousand except per share data
compani report wainwright co estim
sales- licens revenue- total revenue- expensescost good sold- research development- gener administrative- sell marketing- acquisit in-process research total expenses- gain loss operations- income/expenseinterest incom expense- total invest incom other- incom loss provis incom taxes- provis incom taxes- net incom loss net incom loss per share basic net incom loss per share dilut weight averag number share outstand weight averag number share outstand inc
histor balanc sheet financi project
thousand except per share data
compani report wainwright co estim
asset cash market securities- receiv account receivable- prepaid current total current assets- market secur non-current- properti equip assets- total assets- liabil sharehold equitycurr liabilitiesaccount accru relat parti total current liabilities- long-term debt- long-term liabilities- total liabilities- total redeem convert prefer sharehold equitycommon stock- addit paid-in accumul accumul comprehens loss- total sharehold equity- total liabil sharehold equity- viela inc
histor statement flow financi project
thousand except per share data
compani report wainwright co estim
flow oper activitiesnet loss- adjust stock-bas compens acquisit in-process research amort premium discount market secur net- chang oper asset liabilitiesaccount receivable- prepaid current account payabl accru expens relat parti total chang oper asset liabilities- flow oper activities- flow invest activitiespurchas market securities- purchas properti acquisit in-process research flow invest activities- flow financ activitiesproce issuanc common proce exercis common stock options- proce issuanc redeem convert prefer payment defer offer costs- flow financ activities- net increase/ decreas cash cash equivalents- cash equival begin period- cash equival end viela inc
glossari abbrevi
sever autoimmun inflammatori disord nervou system
cluster differenti
autoimmun disord affect gland produc tear saliva
membran protein conduct water cell membran
type antibodi
costimulatori protein found antigen-pres cell
protein primarili express activ cell
rare type dendrit cell
peptid involv cell signal
white blood cell secret antibodi present antigen
white blood cell varieti immune-rel function
b-lymphocyt antigen express cell
cell surfac protein express plasmacytoid dendrit cell
appear circul transient secret antibodi
 cell differenti plasma cell secret antibodi
public compani mention report
rate
rate
rate
argenx se argx rate
astrazeneca plc azn rate
rate
co rate
bristol-my squibb rate
immunov scienc imvt rate
johnson johnson rate
nv rate
novarti ag nv rate
rate
ra rarx rate
roch hold rog vx rate
ucb ucb br rate
co ltd tkphf rate
teva pharmaceut industri teva rate
rate
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
relat compani mention report
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl februari
 wainwright co llc firm member finra sipc regist broker-deal
raghuram selvaraju ph yi chen ph cfa certifi view express report accur reflect
person view subject secur issuer discuss part compens
directli indirectli relat specif recommend view express research report neither
member household offic director advisori board member compani
none research analyst research analyst household financi interest secur inc
inc inc genmab a/ inc seattl
genet inc includ without limit option right warrant futur long short posit
januari neither firm affili benefici class common equiti secur
inc inc inc genmab a/
inc
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst firm and/or research analyst household financi interest secur
bausch health compani inc includ without limit option right warrant futur long short posit
januari neither firm affili benefici class common equiti secur
bausch health compani inc
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens non-invest bank servic
firm affili receiv compens inc bausch health compani inc inc catalyst
pharmaceut inc inc inc invest bank
servic within twelv month seek compens compani mention report invest
bank servic within three month follow public research report
firm affili receiv compens genmab a/ invest bank servic within twelv month
seek compens compani mention report invest bank servic within three
month follow public research report
 wainwright co llc manag co-manag public offer secur genmab a/ past month
firm make market viela inc bausch health compani inc inc
amicu inc genmab a/ momenta pharmaceut inc seattl genet inc date
import disclosur chart found disclaim websit http //hcwco bluematrix com/sellside/
